135 related articles for article (PubMed ID: 9731205)
1. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin resistance and regulation of DNA repair in cAMP-dependent protein kinase mutants.
Liu B; Cvijic ME; Jetzt A; Chin KV
Cell Growth Differ; 1996 Aug; 7(8):1105-12. PubMed ID: 8853907
[TBL] [Abstract][Full Text] [Related]
3. Regulation of P-glycoprotein expression in cyclic AMP-dependent protein kinase mutants.
Cvijic ME; Chin KV
Cell Growth Differ; 1997 Dec; 8(12):1243-7. PubMed ID: 9419412
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin sensitivity in cAMP-dependent protein kinase mutants of Saccharomyces cerevisiae.
Cvijic ME; Yang WL; Chin KV
Anticancer Res; 1998; 18(5A):3187-92. PubMed ID: 9858882
[TBL] [Abstract][Full Text] [Related]
5. Compensatory stabilization of RIIbeta protein, cell cycle deregulation, and growth arrest in colon and prostate carcinoma cells by antisense-directed down-regulation of protein kinase A RIalpha protein.
Nesterova M; Noguchi K; Park YG; Lee YN; Cho-Chung YS
Clin Cancer Res; 2000 Sep; 6(9):3434-41. PubMed ID: 10999726
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention with protein kinase A RIalpha antisense in DMBA-mammary carcinogenesis.
Nesterova MV; Cho-Chung YS
Ann N Y Acad Sci; 2005 Nov; 1058():255-64. PubMed ID: 16394142
[TBL] [Abstract][Full Text] [Related]
7. Flow-cytometric detection of the RI alpha subunit of type I cAMP-dependent protein kinase in human cells.
Pepe S; Ruggiero A; Tortora G; Ciardiello F; Garbi C; Yokozaki H; Cho-Chung YS; Clair T; Skalhegg BS; Bianco AR
Cytometry; 1994 Jan; 15(1):73-9. PubMed ID: 8162827
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
9. DNA topoisomerase II alpha expression is associated with alkylating agent resistance.
Eder JP; Chan VT; Ng SW; Rizvi NA; Zacharoulis S; Teicher BA; Schnipper LE
Cancer Res; 1995 Dec; 55(24):6109-16. PubMed ID: 8521401
[TBL] [Abstract][Full Text] [Related]
10. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
[TBL] [Abstract][Full Text] [Related]
11. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
Li Q; Bostick-Bruton F; Reed E
Anticancer Res; 1998; 18(4A):2283-7. PubMed ID: 9703867
[TBL] [Abstract][Full Text] [Related]
12. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
Nesterova MV; Cho-Chung YS
Clin Cancer Res; 2004 Jul; 10(13):4568-77. PubMed ID: 15240549
[TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Tortora G; Ciardiello F; Damiano V; Pepe S; Bianco C; di Isernia G; Davies SL; North P; Harris AL; Hickson ID
Clin Cancer Res; 1995 Jan; 1(1):49-56. PubMed ID: 9815886
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.
McDaid HM; Cairns MT; Atkinson RJ; McAleer S; Harkin DP; Gilmore P; Johnston PG
Br J Cancer; 1999 Feb; 79(5-6):933-9. PubMed ID: 10070893
[TBL] [Abstract][Full Text] [Related]
15. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
Beale PJ; Rogers P; Boxall F; Sharp SY; Kelland LR
Br J Cancer; 2000 Jan; 82(2):436-40. PubMed ID: 10646901
[TBL] [Abstract][Full Text] [Related]
16. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
Li D; Williams JI; Pietras RJ
Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells.
Qiu YY; Mirkin BL; Dwivedi RS
Cancer Detect Prev; 2005; 29(5):456-63. PubMed ID: 16185816
[TBL] [Abstract][Full Text] [Related]
18. The RI alpha subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells.
Tortora G; Pepe S; Bianco C; Baldassarre G; Budillon A; Clair T; Cho-Chung YS; Bianco AR; Ciardiello F
Oncogene; 1994 Nov; 9(11):3233-40. PubMed ID: 7936647
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a cAMP-dependent protein kinase mutant resistant to cisplatin.
Cvijic ME; Chin KV
Int J Cancer; 1997 Jul; 72(2):345-50. PubMed ID: 9219844
[TBL] [Abstract][Full Text] [Related]
20. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
